| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasm Metastasis | 44 | 2015 | 1095 | 4.390 |
Why?
|
| MAP Kinase Kinase 4 | 16 | 2012 | 67 | 4.200 |
Why?
|
| Genes, Tumor Suppressor | 23 | 2011 | 159 | 2.970 |
Why?
|
| Omentum | 6 | 2020 | 72 | 1.970 |
Why?
|
| Ovarian Neoplasms | 11 | 2020 | 757 | 1.900 |
Why?
|
| Prostatic Neoplasms | 33 | 2011 | 1762 | 1.850 |
Why?
|
| Peritoneal Neoplasms | 4 | 2020 | 181 | 1.360 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2012 | 289 | 1.270 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 6 | 2007 | 102 | 1.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 6 | 2000 | 110 | 0.690 |
Why?
|
| Protein Biosynthesis | 6 | 2009 | 391 | 0.630 |
Why?
|
| Tumor Cells, Cultured | 20 | 2012 | 1057 | 0.630 |
Why?
|
| Animals | 51 | 2020 | 27127 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2011 | 1253 | 0.610 |
Why?
|
| Disease Models, Animal | 8 | 2015 | 2331 | 0.550 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2015 | 1 | 0.540 |
Why?
|
| Mice | 27 | 2020 | 11682 | 0.530 |
Why?
|
| Signal Transduction | 14 | 2014 | 3358 | 0.510 |
Why?
|
| Neoplasms | 6 | 2011 | 2996 | 0.490 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2011 | 71 | 0.480 |
Why?
|
| Biomarkers, Tumor | 7 | 2012 | 1519 | 0.480 |
Why?
|
| Models, Biological | 5 | 2011 | 1764 | 0.470 |
Why?
|
| Cell Division | 9 | 2008 | 696 | 0.460 |
Why?
|
| Membrane Glycoproteins | 3 | 2006 | 431 | 0.420 |
Why?
|
| Rats | 20 | 2011 | 4028 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 2528 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2004 | 65 | 0.390 |
Why?
|
| Humans | 64 | 2020 | 88286 | 0.390 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 64 | 0.380 |
Why?
|
| Adipose Tissue | 1 | 2013 | 253 | 0.380 |
Why?
|
| Up-Regulation | 4 | 2008 | 729 | 0.370 |
Why?
|
| MAP Kinase Kinase 7 | 3 | 2007 | 21 | 0.360 |
Why?
|
| Peptide Initiation Factors | 4 | 1993 | 27 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2011 | 539 | 0.340 |
Why?
|
| Kangai-1 Protein | 3 | 2006 | 3 | 0.340 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 447 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2008 | 80 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 24 | 0.320 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 12 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 1996 | 106 | 0.300 |
Why?
|
| Mice, Nude | 9 | 2014 | 813 | 0.290 |
Why?
|
| Duffy Blood-Group System | 1 | 2006 | 7 | 0.280 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1423 | 0.270 |
Why?
|
| Mice, SCID | 8 | 2006 | 261 | 0.270 |
Why?
|
| Neoplasm Transplantation | 9 | 2020 | 396 | 0.260 |
Why?
|
| Lung Neoplasms | 7 | 2011 | 2325 | 0.260 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 115 | 0.260 |
Why?
|
| Male | 36 | 2011 | 41840 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 289 | 0.250 |
Why?
|
| Chromosome Mapping | 6 | 2004 | 1077 | 0.240 |
Why?
|
| Genes, ras | 3 | 1993 | 97 | 0.240 |
Why?
|
| Receptor Cross-Talk | 1 | 2004 | 34 | 0.240 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 433 | 0.240 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 1999 | 116 | 0.230 |
Why?
|
| Stem Cells | 2 | 2015 | 367 | 0.230 |
Why?
|
| beta-Galactosidase | 3 | 2006 | 73 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 4 | 2006 | 197 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 182 | 0.220 |
Why?
|
| Organ Specificity | 1 | 2004 | 270 | 0.220 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 166 | 0.210 |
Why?
|
| Phosphoproteins | 1 | 2004 | 260 | 0.210 |
Why?
|
| MAP Kinase Kinase 6 | 3 | 2007 | 12 | 0.210 |
Why?
|
| Cell Adhesion | 4 | 2010 | 425 | 0.210 |
Why?
|
| Cell Survival | 3 | 2004 | 979 | 0.210 |
Why?
|
| Naphthalenes | 2 | 1999 | 45 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 1183 | 0.200 |
Why?
|
| Female | 16 | 2020 | 45560 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2011 | 1638 | 0.190 |
Why?
|
| Receptors, CCR1 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 511 | 0.190 |
Why?
|
| Antigens, CD | 2 | 2000 | 463 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2010 | 1787 | 0.180 |
Why?
|
| Chemokines | 1 | 2020 | 74 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2000 | 661 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2012 | 2001 | 0.170 |
Why?
|
| Transfection | 7 | 2005 | 913 | 0.170 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 306 | 0.170 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 19 | 0.170 |
Why?
|
| RNA, Antisense | 3 | 1993 | 15 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 4 | 2010 | 574 | 0.170 |
Why?
|
| Apoptosis | 6 | 2008 | 1713 | 0.160 |
Why?
|
| Cellular Senescence | 3 | 2009 | 103 | 0.160 |
Why?
|
| Heterografts | 2 | 2015 | 102 | 0.160 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2008 | 21 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 307 | 0.150 |
Why?
|
| Enzyme Activation | 3 | 2005 | 698 | 0.150 |
Why?
|
| Macrophages | 1 | 2020 | 572 | 0.150 |
Why?
|
| Cell Movement | 3 | 2005 | 783 | 0.140 |
Why?
|
| Carcinoma | 1 | 2000 | 441 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2000 | 408 | 0.140 |
Why?
|
| Phosphorylation | 5 | 2007 | 1126 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 282 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 5 | 2008 | 928 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 1995 | 103 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2012 | 797 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 4 | 2004 | 364 | 0.130 |
Why?
|
| Repressor Proteins | 2 | 2014 | 418 | 0.130 |
Why?
|
| Genetic Markers | 1 | 1996 | 477 | 0.130 |
Why?
|
| Disease Progression | 4 | 2007 | 1488 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 447 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 726 | 0.120 |
Why?
|
| Azure Stains | 1 | 2013 | 6 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 125 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 330 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2013 | 65 | 0.110 |
Why?
|
| Implants, Experimental | 1 | 2013 | 16 | 0.110 |
Why?
|
| Oxides | 3 | 2002 | 43 | 0.110 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2013 | 79 | 0.110 |
Why?
|
| Peritoneum | 1 | 2013 | 57 | 0.110 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 62 | 0.110 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1992 | 6 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 891 | 0.110 |
Why?
|
| Optical Imaging | 1 | 2013 | 49 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 1998 | 354 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cell Cycle | 2 | 2008 | 508 | 0.100 |
Why?
|
| Iron | 3 | 2002 | 166 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2002 | 392 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2013 | 65 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 1993 | 269 | 0.100 |
Why?
|
| Hybrid Cells | 3 | 2004 | 71 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2005 | 331 | 0.100 |
Why?
|
| G1 Phase | 1 | 2011 | 65 | 0.100 |
Why?
|
| Drug Design | 1 | 2011 | 124 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2000 | 1639 | 0.100 |
Why?
|
| Molecular Biology | 1 | 2010 | 89 | 0.090 |
Why?
|
| Eukaryotic Initiation Factor-4E | 4 | 1993 | 17 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 101 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2011 | 303 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2010 | 172 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 88 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 432 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 697 | 0.090 |
Why?
|
| Cell Death | 2 | 2008 | 262 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2008 | 259 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2008 | 24 | 0.080 |
Why?
|
| Hemagglutinins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 2063 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2011 | 2402 | 0.080 |
Why?
|
| Dactinomycin | 1 | 2008 | 36 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 630 | 0.080 |
Why?
|
| Cycloheximide | 1 | 2008 | 56 | 0.080 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 6 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 371 | 0.080 |
Why?
|
| Quorum Sensing | 1 | 2008 | 27 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 85 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2008 | 69 | 0.080 |
Why?
|
| Transgenes | 1 | 2008 | 182 | 0.080 |
Why?
|
| Contrast Media | 3 | 2002 | 1084 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3191 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 245 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 217 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2020 | 691 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 2972 | 0.070 |
Why?
|
| Gene Expression | 4 | 1995 | 1308 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1846 | 0.070 |
Why?
|
| Models, Immunological | 1 | 2006 | 80 | 0.070 |
Why?
|
| Homeostasis | 1 | 2008 | 407 | 0.070 |
Why?
|
| Ethanol | 1 | 2008 | 250 | 0.060 |
Why?
|
| Hindlimb | 2 | 2002 | 92 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2009 | 551 | 0.060 |
Why?
|
| Plasmids | 2 | 1996 | 292 | 0.060 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2004 | 15 | 0.060 |
Why?
|
| Loss of Heterozygosity | 2 | 2001 | 86 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2007 | 476 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2005 | 162 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 1568 | 0.060 |
Why?
|
| Base Sequence | 4 | 2009 | 2333 | 0.060 |
Why?
|
| DNA Primers | 2 | 2009 | 544 | 0.060 |
Why?
|
| Urothelium | 2 | 2000 | 71 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 5299 | 0.050 |
Why?
|
| Cadherins | 2 | 2000 | 160 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2873 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2004 | 313 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2006 | 1984 | 0.050 |
Why?
|
| Karyotyping | 2 | 1998 | 253 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 113 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2002 | 518 | 0.050 |
Why?
|
| Genes, Suppressor | 1 | 2000 | 2 | 0.050 |
Why?
|
| Metaphase | 1 | 2000 | 25 | 0.050 |
Why?
|
| Kisspeptins | 1 | 2000 | 4 | 0.050 |
Why?
|
| G2 Phase | 1 | 2000 | 34 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2020 | 36 | 0.050 |
Why?
|
| Gene Editing | 1 | 2020 | 42 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 71 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 159 | 0.040 |
Why?
|
| Biomarkers | 1 | 2006 | 1753 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 305 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 20 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1999 | 394 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2002 | 3426 | 0.040 |
Why?
|
| Biotransformation | 1 | 1998 | 50 | 0.040 |
Why?
|
| Neomycin | 1 | 1998 | 7 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 1999 | 99 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1998 | 79 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2002 | 561 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 1881 | 0.040 |
Why?
|
| Flavonoids | 1 | 1999 | 87 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 1999 | 268 | 0.040 |
Why?
|
| Rodentia | 1 | 1998 | 42 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1349 | 0.040 |
Why?
|
| Spermine | 1 | 1998 | 21 | 0.040 |
Why?
|
| Proteins | 2 | 2000 | 786 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 398 | 0.040 |
Why?
|
| Piperidines | 1 | 1999 | 163 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2001 | 566 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2000 | 155 | 0.040 |
Why?
|
| Light | 1 | 1998 | 292 | 0.040 |
Why?
|
| Ferrosoferric Oxide | 3 | 2002 | 18 | 0.040 |
Why?
|
| Magnetite Nanoparticles | 3 | 2002 | 27 | 0.040 |
Why?
|
| Dextrans | 3 | 2002 | 77 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 152 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 1996 | 443 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 269 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1587 | 0.030 |
Why?
|
| Retroviridae | 1 | 1996 | 79 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1995 | 8 | 0.030 |
Why?
|
| Clone Cells | 2 | 1995 | 214 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 129 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 619 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2001 | 1226 | 0.030 |
Why?
|
| Phenotype | 2 | 1999 | 2430 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1998 | 611 | 0.030 |
Why?
|
| Oncogenes | 1 | 1994 | 90 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1993 | 505 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1994 | 109 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1995 | 3030 | 0.030 |
Why?
|
| RNA, Complementary | 1 | 1993 | 8 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2014 | 70 | 0.030 |
Why?
|
| Kinetics | 2 | 1993 | 1528 | 0.030 |
Why?
|
| Cell Line | 2 | 1999 | 2498 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1993 | 223 | 0.030 |
Why?
|
| Polyvinyl Chloride | 1 | 2013 | 8 | 0.030 |
Why?
|
| RNA Caps | 1 | 1993 | 8 | 0.030 |
Why?
|
| Ploidies | 1 | 1993 | 41 | 0.030 |
Why?
|
| Lung | 1 | 1999 | 1241 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1993 | 97 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 170 | 0.030 |
Why?
|
| Materials Testing | 1 | 2013 | 93 | 0.030 |
Why?
|
| Eukaryotic Cells | 1 | 1993 | 44 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1992 | 26 | 0.030 |
Why?
|
| Actins | 2 | 1993 | 456 | 0.030 |
Why?
|
| Ribosomes | 1 | 1993 | 112 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1994 | 594 | 0.030 |
Why?
|
| Abdomen | 1 | 2013 | 121 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 229 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 269 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 417 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2014 | 206 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1993 | 353 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 634 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1993 | 181 | 0.030 |
Why?
|
| Rabbits | 1 | 1993 | 640 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1083 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1994 | 667 | 0.020 |
Why?
|
| Prostate | 1 | 1994 | 391 | 0.020 |
Why?
|
| Mammals | 1 | 1993 | 232 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1993 | 754 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 861 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 95 | 0.020 |
Why?
|
| Mutation | 1 | 2001 | 4090 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Paxillin | 1 | 2008 | 59 | 0.020 |
Why?
|
| United States | 2 | 2002 | 6857 | 0.020 |
Why?
|
| Cholestanols | 1 | 2004 | 2 | 0.020 |
Why?
|
| Leuprolide | 1 | 2004 | 35 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2004 | 72 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1943 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 156 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 477 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2000 | 7 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2000 | 11 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 2000 | 40 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2000 | 32 | 0.010 |
Why?
|
| Cyclins | 1 | 2000 | 83 | 0.010 |
Why?
|
| Body Water | 1 | 2000 | 35 | 0.010 |
Why?
|
| Chromosomes | 1 | 2000 | 97 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 111 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 275 | 0.010 |
Why?
|
| Endothelium | 1 | 2000 | 58 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2000 | 155 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 202 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 902 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 565 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2000 | 380 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 464 | 0.010 |
Why?
|
| Androgens | 1 | 1998 | 173 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2000 | 454 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1999 | 331 | 0.010 |
Why?
|
| Cisplatin | 1 | 1999 | 615 | 0.010 |
Why?
|
| Research Design | 1 | 2000 | 593 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1995 | 74 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 1710 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 647 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1141 | 0.010 |
Why?
|
| Kidney | 1 | 1998 | 1145 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-4F | 1 | 1991 | 2 | 0.010 |
Why?
|
| Polyribosomes | 1 | 1991 | 20 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1991 | 68 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1991 | 176 | 0.010 |
Why?
|
| Aged | 1 | 2008 | 18834 | 0.010 |
Why?
|
| Middle Aged | 1 | 2008 | 25571 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 26230 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1995 | 940 | 0.000 |
Why?
|